Our Chairman in the AFR

The below are from the Q&A with Paul Hopper today.

So starting at the bottom - he took a company that was $3m and turned it into $500m.
SUDA is $5m...

Also, he uses a team of experts to decide on whether to get involved in cancer projects. And clearly he doesnt get involved in them all.
And of course, he decided a year ago, that our Anagralide project was worthy of his precious time.

Good stuff Paul.

You’ve been a biotech entrepreneur for almost 20 years. What does that entail?

I’ll get called from a university in Australia or the United States, where I lived for 11 years, saying they’ve got a really interesting cancer drug.

I go and look at it with a network of experts who help me, because some of this science is pretty deep. I will decide whether we can form a company and raise money to develop the drug

You were chairman of Viralytics, which was sold to Merck in 2018 for $502 million.

Viralytics was started with an idea out of the University of Newcastle. The company was basically broke and had a valuation of $3 million. In 10 years we turned it into $502 million. It was an incredibly good deal.